Somerset, N.J. – April 2, 2014 — Three experts from Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, are to present at the forthcoming ICSE Japan exhibition which takes place at Tokyo Big Sight, Tokyo, Japan, from 9th to 11th of April.
On Wednesday 9th April, at 3.15 pm, Catalent’s Zydis® Fast Dissolve Formulation Manager, Dr. Keiko Tsutsumi, will present “New Local Development Facilities for Zydis, a World Leading Oral Dissolve Technology – Enabling Better Treatments.” Zydis is a unique, freeze-dried oral dosage form that disperses in the mouth, requiring no water. In some cases this can enhance the performance of a drug and can also contribute towards better patient compliance.
“Recent Softgel Innovations: Improving Delivery of More Molecules” is the title of Hironori Kubota, Director of Pharmaceutical Softgels' session on Thursday 10th April at 4 pm. Catalent has recently launched three new softgel products and his presentation will feature the potential patient benefits of OptiGel Micro™, OptiGel Lock™ and OptiGel Bio™. Amongst their many benefits these include easier advanced formulation for protein and peptide drugs, patient benefits such as easier swallowing and the opportunity for improved compliance, and abuse deterrence.
Finally, on Friday 11th April, commencing at 11.45 a.m., Shingo Nakamura, Director of Biologics, will discuss “Accelerated Biosimilar Development and Integrated Solutions for Better Treatments.” His presentation will feature an overview of Catalent’s GPEx® cell line expression technology that produces high-yielding, stable mammalian cell lines and has been successfully applied in the manufacture of more than 500 different recombinant proteins, over 30 of which are now undergoing clinical trials or being supplied commercially.
For further information on ICSE Japan, visit: http://www.cphi.com/japan/home/.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2013 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com